Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2a/2b Study of BMS-650032 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotypes 1 and 4 Chronic Hepatitis C Infection
Brief Summary: The purpose of this study is to identify one or more doses of BMS-650032 that, when used in combination with pegylated-interferon alpha and ribavirin are safe and demonstrate sufficient activity against hepatitis C virus (Genotypes 1 and 4).


Options:
A: Arm Label: ABT-450/r/ABT-267 and ABT-333, plus RBV for 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Ribavirin (RBV) | Arm Label: ABT-450/r/ABT-267 and ABT-333, plus RBV for 24 weeks; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Ribavirin (RBV) | Intervention Type: DRUG; Name: ABT-450/r/ABT-267, ABT-333; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, plus RBV for 12 weeks, ABT-450/r/ABT-267 and ABT-333, plus RBV for 24 weeks | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, plus RBV for 12 weeks, ABT-450/r/ABT-267 and ABT-333, plus RBV for 24 weeks
B: Arm Label: Phase 2a: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: Peginterferon Alfa-2a, Drug: Ribavirin | Arm Label: Phase 2a: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon Alfa-2a, Drug: Ribavirin | Arm Label: Phase 2b: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: Placebo, Drug: Peginterferon Alfa-2a, Drug: Ribavirin | Arm Label: Phase 2b: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon Alfa-2a, Drug: Ribavirin | Intervention Type: DRUG; Name: BMS-650032; Assigned to Arm(s): Phase 2a: Arm 1 | Intervention Type: DRUG; Name: BMS-650032; Assigned to Arm(s): Phase 2b: Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Phase 2a: Arm 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Phase 2b: Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Phase 2b: Arm 2 | Intervention Type: DRUG; Name: Peginterferon Alfa-2a; Assigned to Arm(s): Phase 2a: Arm 1, Phase 2a: Arm 2, Phase 2b: Arm 2 | Intervention Type: DRUG; Name: Peginterferon Alfa-2a; Assigned to Arm(s): Phase 2b: Arm 1 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Phase 2a: Arm 1, Phase 2a: Arm 2, Phase 2b: Arm 2 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Phase 2b: Arm 1
C: Arm Label: 24-wk Vaniprevir 600 mg + Peg-IFN/RBV; Type: EXPERIMENTAL; Interventions: Drug: Vaniprevir, Drug: Pegylated Interferon (Peg-IFN), Drug: Ribavirin (RBV) | Arm Label: 24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV; Type: EXPERIMENTAL; Interventions: Drug: Vaniprevir, Drug: Pegylated Interferon (Peg-IFN), Drug: Ribavirin (RBV), Drug: Placebo (PBO) | Arm Label: 48-wk Vaniprevir 300 mg + Peg-IFN/RBV; Type: EXPERIMENTAL; Interventions: Drug: Vaniprevir, Drug: Pegylated Interferon (Peg-IFN), Drug: Ribavirin (RBV) | Arm Label: 48-wk Vaniprevir 600 mg + Peg-IFN/RBV; Type: EXPERIMENTAL; Interventions: Drug: Vaniprevir, Drug: Pegylated Interferon (Peg-IFN), Drug: Ribavirin (RBV) | Arm Label: 48-wk PBO + Peg-IFN/RBV; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pegylated Interferon (Peg-IFN), Drug: Ribavirin (RBV), Drug: Placebo (PBO) | Intervention Type: DRUG; Name: Vaniprevir; Assigned to Arm(s): 24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV, 24-wk Vaniprevir 600 mg + Peg-IFN/RBV, 48-wk Vaniprevir 300 mg + Peg-IFN/RBV, 48-wk Vaniprevir 600 mg + Peg-IFN/RBV | Intervention Type: DRUG; Name: Pegylated Interferon (Peg-IFN); Assigned to Arm(s): 24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV, 24-wk Vaniprevir 600 mg + Peg-IFN/RBV, 48-wk PBO + Peg-IFN/RBV, 48-wk Vaniprevir 300 mg + Peg-IFN/RBV, 48-wk Vaniprevir 600 mg + Peg-IFN/RBV | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): 24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV, 24-wk Vaniprevir 600 mg + Peg-IFN/RBV, 48-wk PBO + Peg-IFN/RBV, 48-wk Vaniprevir 300 mg + Peg-IFN/RBV, 48-wk Vaniprevir 600 mg + Peg-IFN/RBV | Intervention Type: DRUG; Name: Placebo (PBO); Assigned to Arm(s): 24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV, 48-wk PBO + Peg-IFN/RBV
D: Arm Label: TMC435 100 mg 12 Wks + PR48; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Placebo, Drug: Peg-IFN-alfa-2a (P), Drug: Ribavirin (R) | Arm Label: TMC435 100 mg 24 Wks + PR48; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Placebo, Drug: Peg-IFN-alfa-2a (P), Drug: Ribavirin (R) | Arm Label: TMC435 100 mg 48 Wks + PR48; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Placebo, Drug: Peg-IFN-alfa-2a (P), Drug: Ribavirin (R) | Arm Label: TMC435 150 mg 12 Wks + PR48; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Placebo, Drug: Peg-IFN-alfa-2a (P), Drug: Ribavirin (R) | Arm Label: TMC435 150 mg 24 Wks + PR48; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Placebo, Drug: Peg-IFN-alfa-2a (P), Drug: Ribavirin (R) | Arm Label: TMC435 150 mg 48 Wks + PR48; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Peg-IFN-alfa-2a (P), Drug: Ribavirin (R) | Arm Label: Placebo 48 Wks + PR48; Type: PLACEBO_COMPARATOR; Interventions: Drug: TMC435, Drug: Peg-IFN-alfa-2a (P), Drug: Ribavirin (R) | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): Placebo 48 Wks + PR48, TMC435 100 mg 12 Wks + PR48, TMC435 100 mg 24 Wks + PR48, TMC435 100 mg 48 Wks + PR48, TMC435 150 mg 12 Wks + PR48, TMC435 150 mg 24 Wks + PR48, TMC435 150 mg 48 Wks + PR48 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): TMC435 100 mg 12 Wks + PR48, TMC435 100 mg 24 Wks + PR48, TMC435 100 mg 48 Wks + PR48, TMC435 150 mg 12 Wks + PR48, TMC435 150 mg 24 Wks + PR48 | Intervention Type: DRUG; Name: Peg-IFN-alfa-2a (P); Assigned to Arm(s): Placebo 48 Wks + PR48, TMC435 100 mg 12 Wks + PR48, TMC435 100 mg 24 Wks + PR48, TMC435 100 mg 48 Wks + PR48, TMC435 150 mg 12 Wks + PR48, TMC435 150 mg 24 Wks + PR48, TMC435 150 mg 48 Wks + PR48 | Intervention Type: DRUG; Name: Ribavirin (R); Assigned to Arm(s): Placebo 48 Wks + PR48, TMC435 100 mg 12 Wks + PR48, TMC435 100 mg 24 Wks + PR48, TMC435 100 mg 48 Wks + PR48, TMC435 150 mg 12 Wks + PR48, TMC435 150 mg 24 Wks + PR48, TMC435 150 mg 48 Wks + PR48

Answer: B